Leading psychedelic drug developing company focused on improving mental health MYND Life Sciences. (CSE: MYND) has announced having expanded its intellectual property portfolio majorly to diagnose and monitor the treatment pattern for patients with Major Depressive Disorder (MDD) and other diseases of inflammation.
The company will be doing this through a depression biomarker diagnostic program in which MYND Life has patented Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) as sample preparation methods for diagnostics which improves performance of mass spectrometry (MS) for measurement of pre-selected protein targets.
MYND says this method will assist their research team with their proprietary panel of biomarkers aimed at diagnosing and monitoring major Depressive Disorders. According to MYND’s CEO, Dr. Lyle Oberg, the company is looking forward to commercialize this panel in the first quarter of next year.
“For decades, the diagnosis of depression relied almost exclusively on the various iterations of the DSM manuals in psychiatry, which relies on self-reporting and physician observation of symptoms to make a proxy-based conclusion that is less precise than many other more objective diagnostic tools in the field of medicine. We also believe that this tool has the potential to enable more accurate diagnosis in all depression clinical trials and lead to better monitoring of relapsing disease,” said the CEO.